Actively Recruiting
Thalidomide Therapy for VEOIBD
Led by Children's Hospital of Fudan University · Updated on 2025-05-22
40
Participants Needed
1
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single center, observational study to investigate the clinical outcomes of thalidomide treatment for very early onset inflammatory bowel disease
CONDITIONS
Official Title
Thalidomide Therapy for VEOIBD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with inflammatory bowel disease
- Disease onset less than 6 years old
- Pediatric Crohn's disease Activity Index (PCDAI) greater than 30 or Pediatric Ulcerative Colitis Activity Index (PUCAI) greater than 35
- Patients and their legal guardians willing to receive thalidomide treatment and participate in this study
You will not qualify if you...
- Liver dysfunction
- Allergy to thalidomide
- Presence of neuropathy
- Presence of thrombosis
- Thalidomide treatment in the previous 30 days
- Biologics treatment in the previous 8 weeks
- Not suitable to participate in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Lin Wang
Shanghai, Shanghai Municipality, China, 201102
Actively Recruiting
Research Team
Y
Ying Huang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here